PriceTargets.com logo

Applied Molecular Transport - AMTI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $32.50
  • Forecasted Upside: 9,601.49%
  • Number of Analysts: 5
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.34 As of 03/30/2023 01:00 AM ET
▼ -0.02 (-5.63%)

This chart shows the closing price for AMTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Applied Molecular Transport Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMTI

Analyst Price Target is $32.50
▲ +9,601.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Applied Molecular Transport in the last 3 months. The average price target is $32.50, with a high forecast of $50.00 and a low forecast of $15.00. The average price target represents a 9,601.49% upside from the last price of $0.34.

This chart shows the closing price for AMTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Applied Molecular Transport. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2023Chardan CapitalDowngradeBuy ➝ NeutralLow
3/6/2023Chardan CapitalReiterated RatingBuyLow
2/8/2023Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
1/5/2023Bank of AmericaDowngradeBuy ➝ UnderperformLow
12/27/2022SVB LeerinkReiterated RatingOutperform ➝ Market PerformLow
12/23/2022JMP SecuritiesDowngradeMarket Outperform ➝ Market PerformLow
12/2/2022Chardan CapitalInitiated CoverageBuyLow
11/8/2022SVB LeerinkLower TargetOutperform$21.00 ➝ $15.00Low
7/7/2022Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
5/20/2022SVB LeerinkLower TargetOutperform$60.00 ➝ $21.00Low
5/19/2022JMP SecuritiesLower TargetMarket Outperform$86.00 ➝ $50.00High
10/18/2021JMP SecuritiesReiterated RatingBuyHigh
9/30/2021Jefferies Financial GroupInitiated CoverageBuy$75.00Medium
3/23/2021Jefferies Financial GroupBoost Target$38.00 ➝ $75.00Low
3/17/2021JMP SecuritiesInitiated CoverageOutperform$92.00High
2/25/2021SVB LeerinkBoost TargetOutperform$32.00 ➝ $74.00High
6/30/2020Jefferies Financial GroupInitiated CoverageBuy$38.00 ➝ $38.00Medium
6/30/2020Bank of AmericaInitiated CoverageBuy$34.00Medium
6/30/2020SVB LeerinkInitiated CoverageOutperform$32.00Medium
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Applied Molecular Transport logo
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.34
Low: $0.34
High: $0.38

50 Day Range

MA: $0.52
Low: $0.34
High: $0.68

52 Week Range

Now: $0.34
Low: $0.33
High: $8.00

Volume

124,778 shs

Average Volume

217,450 shs

Market Capitalization

$13.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied Molecular Transport?

The following Wall Street sell-side analysts have issued reports on Applied Molecular Transport in the last twelve months: Bank of America Co., Chardan Capital, Jefferies Financial Group Inc., JMP Securities, and SVB Leerink LLC.
View the latest analyst ratings for AMTI.

What is the current price target for Applied Molecular Transport?

2 Wall Street analysts have set twelve-month price targets for Applied Molecular Transport in the last year. Their average twelve-month price target is $32.50, suggesting a possible upside of 8,927.8%. JMP Securities has the highest price target set, predicting AMTI will reach $50.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $15.00 for Applied Molecular Transport in the next year.
View the latest price targets for AMTI.

What is the current consensus analyst rating for Applied Molecular Transport?

Applied Molecular Transport currently has 2 sell ratings and 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMTI, but not buy more shares or sell existing shares.
View the latest ratings for AMTI.

What other companies compete with Applied Molecular Transport?

Other companies that are similar to Applied Molecular Transport include Gelesis, Regulus Therapeutics, Kazia Therapeutics, Humanigen and Addex Therapeutics. Learn More about companies similar to Applied Molecular Transport.

How do I contact Applied Molecular Transport's investor relations team?

Applied Molecular Transport's physical mailing address is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-392-0420 and its investor relations email address is [email protected] The official website for Applied Molecular Transport is www.appliedmt.com. Learn More about contacing Applied Molecular Transport investor relations.